Bristol-Myers Squibb (BMY) Tops Q2 EPS by 43c, Beats on Revenue; Offers FY26 Guidance

Bristol-Myers Squibb (NYSE: BMY) reported Q2 EPS of $2.04, $0.43 better than the analyst estimate of $1.61. Revenue for the quarter came in at $12.97 billion versus the consensus estimate of $11.71 billion.

GUIDANCE:

Bristol-Myers Squibb sees FY2026 EPS of $6.75-$7.00, versus the consensus of $6.34. Bristol-Myers Squibb sees FY2026 revenue of $49.5-50 billion, versus the consensus of $47.5 billion.

For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.

You May Also Be Interested In

• Vicor raises Q3 2026 revenue guidance on new licensing deal
• U.S. Seeks to Phase Out Russian Uranium Ahead of Full-Ban on Imports - DJ
• Qnity Electronics added to PHLX Semiconductor Sector Index